Robert D. Rosenberg

Robert D. Rosenberg's AcademicInfluence.com Rankings

Robert D. Rosenberg

Biology

#4778

World Rank

#7084

Historical Rank

Biochemistry

#512

World Rank

#600

Historical Rank

biology Degrees

Download Badge

Biology

Robert D. Rosenberg's Degrees

PhD Biochemistry University of California, Berkeley
Bachelors Chemistry University of California, Berkeley

Why Is Robert D. Rosenberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert D. Rosenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The purification and mechanism of action of human antithrombin-heparin cofactor. (1973) (1231)
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry (1999) (1022)
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo (1992) (735)
Activation of coagulation after administration of tumor necrosis factor to normal subjects. (1990) (710)
Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth (1981) (665)
Effect of heparin and heparin fractions on platelet aggregation. (1980) (617)
Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction (1994) (611)
Vascular-bed--specific hemostasis and hypercoagulable states. (1999) (599)
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation (1999) (555)
Anticoagulant Action of Heparin (1973) (486)
Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice (2002) (484)
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. (1994) (452)
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. (1994) (446)
The separation of active and inactive forms of heparin. (1976) (443)
Actions and interactions of antithrombin and heparin. (1975) (436)
Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: In Vivo Studies with Anticoagulant and Nonanticoagulant Heparin (1980) (429)
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. (1987) (424)
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. (1995) (416)
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells (1988) (408)
PR39, a peptide regulator of angiogenesis (2000) (390)
Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? (1997) (383)
Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: II. In Vitro Studies (1980) (338)
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. (1982) (308)
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. (1984) (307)
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells (1985) (287)
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. (1986) (286)
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. (1980) (282)
Vascular Bed–specific Expression of an Endothelial Cell Gene Is Programmed by the Tissue Microenvironment (1997) (282)
Isolation of a src homology 2-containing tyrosine phosphatase. (1992) (282)
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. (1982) (275)
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. (1998) (275)
Natural anticoagulant mechanisms. (1984) (247)
Hypercoagulability in centenarians: the paradox of successful aging. (1995) (243)
Multiple Isoforms of Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase (1999) (238)
Correlation between structure and function of heparin. (1979) (237)
Coagulation Activation Following Estrogen Administration to Postmenopausal Women (1992) (226)
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. (1993) (222)
The absence of the blood clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. (1995) (222)
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta (1990) (221)
Anticoagulantly active heparin-like molecules from vascular tissue. (1984) (220)
Isolation and characterization of endothelial progenitor cells from mouse embryos. (1998) (218)
Factor IX is activated in vivo by the tissue factor mechanism. (1990) (215)
Contribution of monosaccharide residues in heparin binding to antithrombin III. (1985) (213)
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. (1987) (206)
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells (1984) (185)
Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease (2000) (182)
Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. (1994) (182)
Expression of Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase Isoforms Reveals Novel Substrate Specificities* (1999) (178)
Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. (1989) (177)
Inhibition of activated factor XII by antithrombin-heparin cofactor. (1976) (176)
Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. (1992) (174)
Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. (1989) (173)
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. (1985) (172)
Mast cell clones: a model for the analysis of cellular maturation (1982) (172)
Fractionation of low molecular weight heparin species and their interaction with antithrombin. (1979) (171)
Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. (1992) (170)
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. (1989) (170)
Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. (1989) (162)
Inhibition of human factor IXa by human antithrombin. (1975) (160)
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. (1981) (155)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Thrombin generation in acute promyelocytic leukemia. (1984) (152)
Multiple functional domains of the heparin molecule. (1981) (152)
Molecular Cloning and Expression of Mouse and Human cDNAs Encoding Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase* (1997) (151)
Enzymatic synthesis of antithrombin III–binding heparan sulfate pentasaccharide (2003) (145)
Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry. (2002) (145)
The Role of Syndecan Cytoplasmic Domain in Basic Fibroblast Growth Factor-dependent Signal Transduction* (1999) (144)
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. (2000) (144)
The Involvement of Heparan Sulfate (HS) in FGF1/HS/FGFR1 Signaling Complex* (2003) (142)
The inhibition of human plasmin by human antithrombin-heparin cofactor. (1974) (142)
Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. (2003) (140)
Isolation and characterization of heparin from human lung. (1979) (139)
Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans (2008) (138)
Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. (1998) (138)
PDGF mediates cardiac microvascular communication. (1998) (134)
Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. (1992) (134)
DETECTION OF FACTOR X ACTIVATION IN HUMANS (1989) (134)
Heparin inhibition of smooth muscle cell proliferation: A cellular site of action (1986) (134)
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site (1991) (133)
Molecular Cloning and Characterization of a Human Uronyl 2-Sulfotransferase That Sulfates Iduronyl and Glucuronyl Residues in Dermatan/Chondroitin Sulfate* (1999) (129)
Binding of lipoprotein lipase to endothelial cells in culture. (1981) (126)
Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. (1995) (125)
Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. (1994) (124)
Purification and properties of human platelet heparitinase. (1982) (123)
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. (1987) (123)
Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. (1987) (122)
Molecular enhancement of porcine cardiac chronotropy (2001) (122)
The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men (1995) (119)
Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase* (1996) (118)
Protection of factor Xa from neutralization by the heparin-antithrombin complex. (1983) (117)
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. (1988) (116)
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. (1985) (114)
c-myc in vasculoproliferative disease. (1995) (111)
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. (1989) (108)
Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. (1987) (105)
The plasma kallikrein–kinin system and risk of cardiovascular disease in men (2007) (104)
Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. (1985) (103)
Activation of the Coagulant Pathway in Cigarette Smokers (1998) (100)
Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase-3A SulfatesN-Unsubstituted Glucosamine Residues* (1999) (99)
Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. (1992) (98)
Structure-function relationships of heparin species. (1978) (98)
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. (1983) (96)
Detection of protein C activation in humans. (1984) (96)
A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. (1977) (96)
Heparin with two binding sites for antithrombin or platelet factor 4. (1982) (95)
Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. (1991) (95)
Characterization of a thrombomodulin cDNA reveals structural similarity to the low density lipoprotein receptor. (1986) (94)
Evaluation of critical groups required for the binding of heparin to antithrombin. (1984) (93)
Molecular heterogeneity of inherited antithrombin III deficiency. (1983) (92)
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. (1994) (92)
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway (2004) (92)
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. (1994) (92)
Targeting of human eNOS promoter to the Hprt locus of mice leads to tissue-restricted transgene expression. (2000) (87)
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. (1995) (86)
The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and F1 + 2. (1979) (86)
6-O-Sulfotransferase-1 Represents a Critical Enzyme in the Anticoagulant Heparan Sulfate Biosynthetic Pathway* (2001) (85)
Characterization of ryudocan glycosaminoglycan acceptor sites. (1994) (85)
The interaction of GATA-binding proteins and basal transcription factors with GATA box-containing core promoters. A model of tissue-specific gene expression. (1994) (85)
Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. (1998) (84)
Temporal and spatial pattern of expression of the HDL receptor SR-BI during murine embryogenesis. (1998) (83)
Role of antithrombin III as a regulator of in vivo coagulation. (1991) (82)
The binding properties of human complement component C1q. Interaction with mucopolysaccharides. (1983) (81)
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. (1990) (81)
Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation (1987) (81)
Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. (1975) (80)
Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. (1983) (80)
Mice deficient in heparan sulfate 3-O-sulfotransferase-1: Normal hemostasis with unexpected perinatal phenotypes (2002) (79)
Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction (2000) (78)
A murine model of myocardial microvascular thrombosis. (1999) (76)
Transforming Growth Factor-β1-mediated Inhibition of the flk-1/KDR Gene Is Mediated by a 5′-Untranslated Region Palindromic GATA Site* (2001) (76)
The binding of low molecular weight heparin to hemostatic enzymes. (1980) (74)
Pathway-specific regulation of the synthesis of anticoagulantly active heparan sulfate. (1994) (73)
Highly active heparin species with multiple binding sites for antithrombin. (1979) (73)
Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor (1987) (71)
The Absence of the Blood Clotting Regulator Thrombomodulin Causes Embryonic Lethality in Mice Before Development of a Functional Cardiovascular System (1995) (71)
Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. (1992) (70)
Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. (1998) (70)
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. (1993) (70)
The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. (1980) (70)
Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. (1983) (69)
Regulation of vascular smooth muscle cell proliferation by plasma membrane Ca(2+)-ATPase. (1997) (69)
The Effect of Precursor Structures on the Action of Glucosaminyl 3-O-Sulfotransferase-1 and the Biosynthesis of Anticoagulant Heparan Sulfate* (2001) (68)
Heparin, antithrombin, and abnormal clotting. (1978) (68)
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. (1992) (66)
Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma. (1987) (65)
Thrombogenic potential of human coronary atherosclerotic plaques. (2001) (65)
Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. (1991) (64)
Inherited antithrombin-III deficiency causing mesenteric venous infarction: a new clinical entity. (1975) (64)
A vascular bed–specific pathway regulates cardiac expression of endothelial nitric oxide synthase (1999) (64)
Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease (1992) (63)
Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. (1987) (63)
Microvascular heparin-like species with anticoagulant activity. (1983) (61)
Sequence variation in heparin octasaccharides with high affinity for antithrombin III. (1984) (61)
Developmentally regulated gene expression of thrombomodulin in postimplantation mouse embryos. (1996) (60)
Targeting the Hprt locus in mice reveals differential regulation of Tie2 gene expression in the endothelium. (2000) (60)
In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. (1987) (60)
Coagulation activation and long-term outcome in acute coronary syndromes. (2003) (60)
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate (1991) (59)
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. (2000) (57)
Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
Targeting of transgene expression to the vascular endothelium of mice by homologous recombination at the thrombomodulin locus. (1996) (57)
Chemoenzymatic Synthesis of Classical and Non-classical Anticoagulant Heparan Sulfate Polysaccharides* (2003) (56)
Cloned mouse cells with natural killer function and cloned suppressor T cells express ultrastructural and biochemical features not shared by cloned inducer T cells (1983) (55)
Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. (1999) (55)
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. (1997) (54)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
Regulation of megakaryocyte ploidy in vivo in the rat. (1990) (53)
Multiple bovine thrombin components. (1970) (52)
c-Myb-dependent cell cycle progression and Ca2+ storage in cultured vascular smooth muscle cells. (1997) (51)
A new strategy for defining critical functional groups on heparan sulfate (2002) (50)
Antithrombin-heparin cofactor. (1976) (50)
Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells. (1992) (48)
Circular dichroism spectroscopy of heparin-antithrombin interactions. (1982) (48)
Heparin‐like molecules regulate the number of epidermal growth factor receptors on vascular smooth muscle cells (1988) (48)
Role of Endothelial Cell Surface Heparin‐like Polysaccharides a (1989) (47)
The principal neuronal gD-type 3-O-sulfotransferases and their products in central and peripheral nervous system tissues. (2007) (47)
Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. (1987) (47)
Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). (1992) (47)
A New Haemorrhagic Disorder with Defective Fibrin Stabilization and Cryofibrinogenaemia (1974) (47)
Enhancement of migration inhibitory factor activity by plasma esterase inhibitors. (1975) (46)
Activation markers of coagulation. (1994) (45)
Interaction of human platelets with heparinized agarose gel. (1978) (44)
Anticoagulantly active heparin-like molecules from mast cell-deficient mice. (1986) (44)
Modulation of Nucleotide Triphosphate Diphosphohydrolase-1 (NTPDase-1)/cd39 in Xenograft Rejection (1999) (44)
Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. (1991) (43)
Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice. (2002) (42)
Coagulation activation and long-term outcome in acute coronary syndromes Running title: Coagulation activation and long-term outcome in CHD Section heading: Clinical observation (2003) (42)
c-myb affects intracellular calcium handling in vascular smooth muscle cells. (1995) (41)
Regulation of Vascular Bed–Specific Prothrombotic Potential (2001) (41)
Characterization of a cell mutant specifically defective in the synthesis of anticoagulantly active heparan sulfate. (1994) (41)
Haemostatic changes that constitute the hypercoagulable state (1991) (40)
Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. (1984) (39)
Cell-free Synthesis of Anticoagulant Heparan Sulfate Reveals a Limiting Converting Activity That Modifies an Excess Precursor Pool* (1996) (38)
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. (1977) (38)
The proto-oncogene c-myb mediates an intracellular calcium rise during the late G1 phase of the cell cycle. (1993) (36)
Anticoagulant Heparan Sulfate Precursor Structures in F9 Embryonal Carcinoma Cells* (1999) (36)
Portable sulphotransferase domain determines sequence specificity of heparan sulphate 3-O-sulphotransferases. (2001) (36)
Comparison of the Effects of Regional Ischemia , Hypoxia , Hyperkalemia , and Acidosis on Intracellular and Extracellular Potentials and Metabolism in the Isolated Porcine Heart (2005) (35)
Transcriptional regulation of the thrombomodulin gene. (1992) (35)
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. (1983) (34)
The Retinoic Acid and cAMP-dependent Up-regulation of 3-O-Sulfotransferase-1 Leads to a Dramatic Augmentation of Anticoagulantly Active Heparan Sulfate Biosynthesis in F9 Embryonal Carcinoma Cells* (1998) (34)
Vascular Smooth Muscle Cell Proliferation: Basic Investigations and New Therapeutic Approaches (1993) (34)
Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. (1997) (33)
Ets Motifs Are Necessary for Endothelial Cell–Specific Expression of a 723-bp Tie-2 Promoter/Enhancer in Hprt Targeted Transgenic Mice (2003) (32)
Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. (1999) (31)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. (1993) (31)
A vascular bed-specific pathway. (1999) (30)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency (1993) (30)
Determining Heparan Sulfate Structure in the Vicinity of Specific Sulfotransferase Recognition Sites by Mass Spectrometry* (2004) (30)
Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin. (2003) (29)
Biologic actions of heparin. (1977) (29)
Catalysis of the generation of thrombin-antithrombin complex by insoluble anticoagulant polystyrene derivatives. (1984) (28)
Analysis of megakaryocyte ploidy in rat bone marrow cultures. (1989) (28)
Mapping critical biological motifs and biosynthetic pathways of heparan sulfate. (2004) (27)
Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery (1994) (27)
The interaction of heparin with thrombin and antithrombin. (1980) (27)
Light-induced 3-O-Sulfotransferase Expression Alters Pineal Heparan Sulfate Fine Structure (2004) (27)
Role of heparin and heparinlike molecules in thrombosis and atherosclerosis. (1985) (27)
Interaction of factor XIa and antithrombin in the presence and absence of heparin. (1986) (27)
The Effect of Heparin on Factor XIa and Plasmin (1975) (27)
Thrombin generation in non-cardioembolic stroke subtypes (2004) (27)
Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system". (1985) (26)
Targeted expression of a conditional oncogene in hematopoietic cells of transgenic mice (1993) (26)
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris (2000) (25)
CD39/vascular ATP diphosphohydrolase modulates xenograft survival. (2000) (25)
Perspectives Series: Cell Adhesion in Vascular Biology (1997) (24)
Endothelium, heparin, and the regulation of vascular smooth muscle cell growth (1984) (24)
Affinity of purified thrombin or antithrombin III for two insoluble anticoagulant polystyrene derivatives: I. In vitro adsorption studies. (1983) (24)
Effect of Low‐Intensity Warfarin Anticoagulation on Level of Activity of the Hemostatic System in Patients With Atrial Fibrillation (1993) (23)
The role of tryptophan residues in heparin-antithrombin interactions. (1984) (23)
c‐Myb function in fibroblasts (1997) (22)
Human ryudocan core protein: molecular cloning and characterization of the cDNA, and chromosomal localization of the gene. (1993) (22)
Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. (1989) (22)
Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence. (1990) (22)
Biochemistry and pharmacology of low molecular weight heparin. (1997) (21)
The Binding Properties of Human Complement Component Clq (1983) (21)
Factor XIa Induced Activation of the Intrinsic Cascade In Vivo (1996) (21)
Adsorption of purified thrombin or antithrombin III for two insoluble anticoagulant polystyrene derivatives: II. Competition with the other plasma proteins. (1984) (20)
Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(β‐aminoethyl ether) N,N′‐tetraacetic acid‐AM on the survival and function of autologous baboon platelets stored at 4°C for as long as 5 days (2004) (20)
Determinants of plasma factor VIIa levels in humans. (1995) (19)
Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. (1989) (18)
Thrombomodulin Gene Disruption and Mutation in Mice (1997) (17)
Heparin Action (1974) (15)
Prothrombin activation fragment assay. (1993) (15)
The role of specific forms of heparan sulfate in regulating blood vessel wall function. (1986) (15)
A rapid and sensitive proteolytic assay for human plasminogen and plasmin using radioiodinated α-casein (1977) (15)
A rapid and sensitive proteolytic assay for human plasminogen and plasmin using radioiodinated α-casein (1977) (15)
Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin. (1976) (14)
Role of heparan sulfate in dextral heart looping in chick. (2004) (14)
Isolation and characterization of ryudocan and syndecan heparan sulfate proteoglycans, core proteins, and cDNAs from a rat endothelial cell line. (1993) (14)
Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. (1995) (13)
Relationship between platelet secretion and prothrombin cleavage in native whole blood. (1981) (13)
Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma. (1987) (13)
Mouse mast cell clones: modulation of functional maturity in vitro. (1983) (13)
HEPARINIZED SURFACES—A COMMENT * (1977) (12)
Anticoagulantly active heparin-like molecules from cultured fibroblasts. (1986) (12)
Atherogenic Regulation by Heparin‐like Molecules a (1985) (11)
Differential partition of anticoagulant heparan sulfate proteoglycans synthesized by endothelial and fibroblastic cell lines (1994) (11)
Determinants of plasma factor VIIa levels in humans (1995) (11)
Heparin-like molecules as regulators of atherogenesis. (1984) (11)
The biochemistry and pathophysiology of the prethrombotic state. (1987) (11)
Heparan Sulfate D -Glucosaminyl 3- O -Sulfotransferase-1, -2, -3, and -4 (2002) (10)
New insights into hypercoagulable states. (1986) (10)
New Approaches for Defining the Molecular Basis of Anticoagulantly Active Heparan Sulfate Production (1991) (10)
Detection of a prethrombotic state (1994) (9)
Binding properties of human thrombospondin: interaction with mucopolysaccharides. (1987) (9)
The Biochemistry and Physiology of Anticoagulantly Active Heparin-like Molecules (1988) (9)
Molecular changes associated with proteolysis of bovine factor V by thrombin. (1975) (8)
Does a prethrombotic state exist? If so, what is it? (1992) (7)
Coagulation-fibrinolytic mechanism and the action of heparin. (1975) (7)
Diagnosis of candidal infection of the prostate by transrectal ultrasonography and biopsy (1992) (7)
Inhibition of smooth muscle cell proliferation by heparin‐like molecules (1986) (7)
Is Factor D of the Alternative Pathway a Fragment of Thrombin? (1978) (7)
Botrocetin agglutination of rat megakaryocytes: a rapid method for megakaryocyte isolation. (1992) (6)
Selection of an HEL-derived cell line expressing high levels of platelet factor 4. (1993) (5)
The Function and Structure of the Heparin Molecule (1983) (5)
[30] Platelet heparitinase (1989) (4)
Role of Heparin-Like Molecules in Atherogenesis (1983) (4)
Selection of an HEL-derived cell line expressing high levels of platelet factor 4 (1993) (4)
Increased incidence of neoplasia with persistent activation of the of the digestive tract in men coagulant pathway (2004) (3)
Assays for hypercoagulability. (1978) (3)
Platelets contain several inhibitors of megakaryocyte growth and ploidization. (1990) (3)
Specific Activities of Bovine Thrombin and Thrombin Components (1972) (3)
rmIL-6 stimulates the transcriptional activity of the rat PF4 gene. (1995) (3)
Purification and properties of guinea pig antithrombin III. (1979) (3)
Conformational changes in human prothrombin as detected by antibody populations. (1989) (3)
Advances in the understanding of the anticoagulant function of heparin. (1975) (2)
The binding porperties of human complement C1q; Interaction with mucopolysaccharides (1982) (2)
Structure-Function Relationships Of Heparin (1981) (2)
New approaches for defining sequence specific synthesis of heparan sulfate chains. (1992) (2)
Antithrombin III and its Interactions with Heparin (1977) (2)
Determinants of coagulation activation in humans. (1996) (2)
Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
Control of Cardiovascular Biology through the Synthesis of Heparan Sulfate Proteoglycans Bearing Specific GAG Structures (1998) (1)
Differential Regulation of the vWF and Flt-1 Promoters in the Endothelium of Hprt-Targeted Mice (2002) (1)
Subject Index, Vol. 26 (suppl 1), 1996 (1996) (1)
Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? (1997) (1)
A rapid and sensitive proteolytic assay for human plasminogen and plasmin using radioiodinated alpha-casein. (1977) (1)
Heparin-Coated Surfaces that bind Antithrombin have Reduced Platelet Reactivity (1979) (1)
…and surreal antisense? (1996) (1)
Anticoagulant Activity Of Heparan Sulfate From Cerebral Microvascular Tissue (1981) (1)
The Isolation and Characterization of a Specific Antibody Population Directed Against the Prothrombin Activation Fragments Fz and F , + 2 * (2002) (1)
Purification of Heparan Sulfate (1996) (1)
Interactions of Some Plasmatic Proteins with Anticoagulant Polystyrene Resins: Mechanism of Catalytic Activity Towards the Thrombin— Antithrombin Reaction (1983) (0)
provides a high-throughput alternative to in vivo enhancer analyses Single site-specific integration targeting coupled with embryonic stem cell differentiation (2015) (0)
Title Page / Table of Contents, Vol. 23, Supplement 1, 1993 (1993) (0)
Ryudocan, Its Molecular Structure and Function (1995) (0)
Cytokines and thrombosis (1992) (0)
and smooth muscle cells in culture monophosphate on thrombomodulin expression by endothelial cells different effects of tumor necrosis factor and cyclic adenosine Expression of thrombomodulin by smooth muscle cells in culture (2011) (0)
Insufficiency, Activation, and Arterial Thrombosis New Tricks for Old Dogs: Nonthrombotic Effects of Thrombin in Vessel Wall Biology Regulation of Vascular Bed–Specific Prothrombotic Potential Insights Into Mechanisms of Thrombosis From Genetic Models Regulation of Vascular Bed–Specific Prothromboti (2001) (0)
syndromes Coagulation activation and long-term outcome in acute coronary (2013) (0)
A murine model of myocardial microvascular thrombosis this access benefits you. Your story matters (1999) (0)
Diagnosis of myocardial disease or stroke using factor ix activation peptide (1999) (0)
ANTITHROMBIN III CONCENTRATE (AT-III) FOR PROPHYLAXIS ANDTREATMENT OF CONGENITAL AND ACQUIREDAT-III DEFCIENCY (1987) (0)
Activation of Human Pro&on&in by Highly Purified Human Factors V and XB in the Presence of Human Antithrombin” (2002) (0)
Kinetics of inhibitors and the mechanisms of action of antithrombin III. (1981) (0)
Transient decrease of thrombin generation during hirudin treatment in patients with acute coronary syndromes (1998) (0)
Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders. (2002) (0)
The in Vivo Effects of Heparin Fractions on the Development of Lung Metastasis in Murine Fibrosarcoma a (1986) (0)
Structure-function relationships of heparin species ( purification of highly active heparin / partial sequence of heparin / chemical composition of heparin ) (0)
Traitement localise aux oligonucleotides (1992) (0)
Subject Index, Vol. 23, 1993 (1993) (0)
Galactosaminoglycan Uronyl 2-Sulfotransferase (2002) (0)
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) (2003) (0)
Heparin from Human Lung (1979) (0)
Title Page / Table of Contents, Vol. 26, Supplement 1, 1996 (1996) (0)
Interaction of Factor XIa and Antithrombin in the Presence 1488 Blood (2005) (0)
HUMAN THROMBOMODULIN cDNA:SEQUENCE AND TRANSLATED STRUCTURE (1987) (0)
Molecular control of intracellular calcium levels in vascular smooth muscle cells (1994) (0)
Structural Elucidation of Heparan Sulfate-Like Polysaccharides Using Miniaturized LC/MS (2004) (0)
4894440 Method of isolating megakaryocyte stimulatory factor (1990) (0)
Humanvon Willebrand factor genesequencestarget expression to a subpopulation ofendothelial cells intransgenic mice (1995) (0)
c-Myb in Smooth Muscle Cells. (1996) (0)
Enzymatic Synthesis of Heparan Sulfate (2004) (0)
THE BINDING OF ANTITHROMBIN TO CAPILLARY ENDOTHELIAL CELLS GROWN IN VITRO (1987) (0)
Expression cloning of LDLB, a g function and assembly of the ldl( (2016) (0)
Inhibition Of Platelet-Associated Factor Xa By Heparin-Antithrombin (1981) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert D. Rosenberg?

Robert D. Rosenberg is affiliated with the following schools: